Report of Foreign Issuer (6-k)
September 09 2019 - 08:41AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of the
Securities Exchange Act of 1934
For
the month of September 2019
Commission
File Number: 001-37643
KITOV
PHARMA LTD.
(Translation
of registrant’s name into English)
One
Azrieli Center, Round Tower,
132
Menachem Begin Road, Tel Aviv 6701101, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Kitov
Pharma Ltd. (the “Company” or the “Registrant”) is announcing that on September 9, 2019, the Company issued
a press release “Kitov Pharma Presents Newly Released Data for NT-219 in Reversing Pancreatic Cancer Drug Resistance,”
which is attached hereto as Exhibit 99.1.
This
Form 6-K, including the entire Exhibit 99.1 attached hereto, is hereby incorporated
by reference into each of the Registrant’s Registration Statements on Form F-3 filed with the Securities and Exchange Commission
on December 12, 2016 (Registration file numbers 333-207117, 333-211477 and 333-215037), the Registrant’s Registration Statement
on Form S-8 filed with the Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478), the Registrant’s
Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number
333-218538), the Registrant’s Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange
Commission on July 16, 2018 (Registration file number 333-226195), and the Registrant’s Registration Statement on Form S-8
filed with the Securities and Exchange Commission on March 28, 2019 (Registration file number 333-230584).
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
KITOV PHARMA LTD.
|
|
|
|
September 9, 2019
|
By:
|
/s/
Isaac Israel
|
|
|
Isaac Israel
|
|
|
CEO & Director
|
2
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Feb 2024 to Mar 2024
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Mar 2023 to Mar 2024